QPS has adopted the Oracle Argus Safety Database to boost its pharmacovigilance systems for clinical trials, enhancing ...

Sanofi’s Teizeild wins EU approval as the first disease-modifying therapy to delay stage 3 type 1 diabetes in people eight and older with stage 2 disease, offering a new early intervention option.

GUILDFORD, SURREY / ACCESS Newswire / January 16, 2026 / CelLBxHealth plc (AIM:CLBX), a leader in circulating tumour cell (CTC) intelligence, with tests and services supporting research, drug ...

Portal Innovations announced continued growth at Portal Atlanta at Science Square, with the addition of seven new member ...

Nummular eczema is a debilitating skin condition that is distinct from atopic dermatitis but involves similar disease ...

FillPoint Health, a URAC- and ACHC-accredited specialty pharmacy and management services organization (MSO) and a Lyceum ...

Healthcare executive and consultant Wendy Gregg, MSW, MBA, continues to build sustainable healthcare programs that expand ...

Biotechnology--InterAx Biotech Ltd (“InterAx”) and Alveus Therapeutics Inc. (“Alveus”) today announced a strategic research ...

Qualified Customers may now purchase Tru Niagen at using HSA/FSA funds with a Truemed Letter of Medical Necessity (LMN)LOS ...

Several recent steps move the closure toward commercializationNew studies confirm the system’s usability and ...

FutureWise Research, a global leader in healthcare market intelligence and analysis, today announced the release of its ...

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the innovative tissue-healing medical device company ...